BMI View: Hong Kong was in the past an attractive commercial prospect, largely propped by the widespread use of patented medicines. However, the climate of cost-containment over the past decade represents and the rising prominence of the pharmaceutical market of mainland China have somewhat diminished the interest in the Special Administrative Region (SAR), especially given its limited population numbers. Nevertheless, the prevalence of non-communicable diseases will continue to provide commercial opportunities for international drugmakers, as will its relatively advanced regulatory regime.
Headline Expenditure Projections
?? Pharmaceuticals: HKD7.98bn (US$1.03bn) in 2010 to HKD8.65bn (US$1.11bn) in 2011; +8.5% in local currency terms and +8.4% in US dollar terms. Forecast up slightly from Q311 due to macroeconomic factors.
?? Healthcare: HKD83.01bn (US$10.69bn) in 2010 to HKD86.11bn (US$11.08bn) in 2011; +3.7% in local currency terms and +3.7% in US dollar terms. Forecast up slightly from Q311 due to macroeconomic factors.
?? Medical devices: HKD4.10bn (US$527mn) in 2010 to HKD4.21bn (US$542mn) in 2011; +2.8% in local currency terms and +2.8% in US dollar terms. Forecast up slightly from Q311 due to macroeconomic factors.
Business Environment Rating: Hong Kong’s composite score for Q411 stands at an unchanged 60.2, which again places it seventh of the 17 markets surveyed in BMI’s proprietary Business Environment Ratings (BERs) matrix. The SAR’s reward profile, dragged down by market maturity and small population numbers, remains considerably less attractive than its risk environment.
Key Trends & Developments
?? In June 2011, Japanese company Takeda Pharmaceutical and US pharmaceutical firm Eli Lilly entered an agreement to sell Evista (raloxifene HCl tablets) in seven Asian nations – including Hong Kong. Evista is approved and marketed to treat and prevent osteoporosis in postmenopausal women in all the regions, as well as to reduce the risk of breast cancer in the Philippines, Singapore and Thailand.
?? About one in every 10 adults in Hong Kong has been found to be a carrier of hepatitis B virus, reported China Daily in August 2011. Of a sample of more than 1,900 citizens, the majority were found to be unaware of the disease and to have overlooked the requirement for vaccination or prevention, which indicates a huge unmet treatment potential. However, the younger generation – born after 1988 – have received mandatory free hepatitis B vaccination in the country.
BMI Economic View: We have revised our Hong Kong 2011 real GDP growth forecast from 4.1% to 5.0% on the back of stronger than expected Q111 growth, which should provide some assistance to government and private finances. However, as inflationary headwinds and a mainland Chinese economic slowdown will weigh on growth, we do not expect major investment in social projects, despite the upcoming elections. We have also revised our Hong Kong 2011 average consumer price inflation forecast upwards to 4.3% from 4.0% due to elevated price pressures in the mainland.
BMI Political View: Hong Kong will soon enter an election cycle, with district council elections scheduled for November and legislative elections set to be held in 2012. A new Chief Executive will also be chosen in 2012, but there is no clear frontrunner at this point given that Beijing has yet to back any particular candidate. Key challenges the next chief executive and administration have to tackle will likely centre on housing and the widening wealth gap, which is also translating into the realm of healthcare. Nevertheless, and regardless of the results, we expect Hong Kong to maintain its strong business environment appeal.

[Studien Infos ausblenden]

Executive Summary 6
SWOT Analysis 8
Hong Kong Pharmaceuticals And Healthcare Industry SWOT 8
Hong Kong Political SWOT 9
Hong Kong Economic SWOT 9
Hong Kong Business Environment SWOT 10
Pharmaceutical Business Environment Ratings 11
Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q411 11
Rewards 12
Risks 12
Hong Kong – Market Summary 14
Regulatory Regime 15
Table: Number of Processed Applications in Hong Kong 15
Recent Regulatory Developments 16
Table: Chronology Of Drug Incidents In Hong Kong March-May 2009 17
Pharmaceutical Trade Regulations 18
Intellectual Property Issues 19
Counterfeit Drugs 19
Pricing and Reimbursement Regime 20
Public Procurement of Medicines 21
Industry Trends and Developments 22
Epidemiology 22
Table: Leading Causes Of Death In Hong Kong, 2001-2008 22
Non-Communicable Diseases 23
Communicable Diseases 24
Healthcare Sector 25
Healthcare Sector Reforms 26
Healthcare Financing 27
Recent Developments in Healthcare Financing 28
Table: Hong Kong's Department of Health – Expenditure Breakdown (HKDmn) 29
Healthcare Insurance 29
Biotechnology 30
Clinical Trials 31
Medical Devices 32
Table: Examples Of Medical Devices in Hong Kong 33
Recent Developments in the Medical Devices Market 34
Industry Forecast Scenario 35
Overall Market Forecast 35
Table: Pharmaceutical Sales Indicators 2007-2015 36
Key Growth Factors – Industry 37
Table: Healthcare Expenditure Indicators 2007-2015 38
Table: Government Healthcare Expenditure Indicators 2007-2015 39
Table: Private Healthcare Expenditure Indicators 2007-2015 39
Key Growth Factors – Macroeconomic 40
Table: Hong Kong – Economic Activity 43
Prescription Drug Market Forecast 44
Table: Prescription Drug Sales Indicators 2007-2015 45
Patented Drug Market Forecast 46
Table: Patented Drug Market Indicators 2007-2015 47
Generic Drug Market Forecast 48
Table: Generic Drug Sales Indicators 2007-2015 49
OTC Medicine Market Forecast 50
Table: OTC Medicine Sales Indicators 2007-2015 51
Medical Device Market Forecast 52
Table: Medical Devices Sales Indicators 2007-2015 53
Pharmaceutical Trade Forecast 54
Table: Exports and Imports Indicators 2007-2015 55
Other Healthcare Indicators 56
Key Risks to BMI’s Forecast Scenario 57
Competitive Landscape 58
Pharmaceutical Industry 58
Traditional Chinese Medicines 59
Recent Industry Developments 59
Pharmaceutical Supply Chain 62
Retail Pharmacy Sector 63
Company Profiles 64
Indigenous Companies 64
Wuyi International Pharmaceutical 64
CK Life Sciences 66
South Asia Pharmamedic 69
C&Y Pharmaceutical Investment 70
Vida Laboratories 71
Multinationals 73
GlaxoSmithKline 73
Pfizer 75
Sanofi-Aventis 77
Merck & Co 79
Novartis 81
Country Snapshot: Hong Kong Demographic Data 83
Section 1: Population 83
Table: Demographic Indicators, 2005-2030 83
Table: Rural/Urban Breakdown 84
Section 2: Education And Healthcare 84
Table: Education, 2002-2005 84
Table: Vital Statistics, 2005-2030 84
Section 3: Labour Market And Spending Power 85
Table: Employment Indicators, 2001-2006 85
Table: Consumer Expenditure, 2000-2012 (US$) 85
Table: Average Annual Wages, 2005-2012 86
Glossary 87
BMI Methodology 89
How We Generate Our Pharmaceutical Industry Forecasts 89
Pharmaceuticals Business Environment Ratings 90
Risk/Reward Ratings Methodology 90
Ratings Overview 90
Table: Pharmaceutical Business Environment Indicators 91
Weighting 92
Table: Weighting Of Components 92
Sources 92
[Inhaltsverzeichnis ausblenden]